[PDF][PDF] Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials
D Miles, N Harbeck, B Escudier, H Hurwitz, L Saltz… - J Clin Oncol, 2011 - academia.edu
D Miles, N Harbeck, B Escudier, H Hurwitz, L Saltz, E Van Cutsem, J Cassidy, B Mueller…
J Clin Oncol, 2011•academia.eduPurpose Preclinical studies have suggested accelerated tumor growth, local invasion, and
distant metastasis after withdrawal of treatment with some antiangiogenic agents. To
investigate whether discontinuation of bevacizumab treatment is associated with
accelerated disease progression or increased mortality, we retrospectively analyzed five
randomized, placebo-controlled phase III studies in 4,205 patients with breast, colorectal,
renal, and pancreatic cancer.
distant metastasis after withdrawal of treatment with some antiangiogenic agents. To
investigate whether discontinuation of bevacizumab treatment is associated with
accelerated disease progression or increased mortality, we retrospectively analyzed five
randomized, placebo-controlled phase III studies in 4,205 patients with breast, colorectal,
renal, and pancreatic cancer.
Purpose
Preclinical studies have suggested accelerated tumor growth, local invasion, and distant metastasis after withdrawal of treatment with some antiangiogenic agents. To investigate whether discontinuation of bevacizumab treatment is associated with accelerated disease progression or increased mortality, we retrospectively analyzed five randomized, placebo-controlled phase III studies in 4,205 patients with breast, colorectal, renal, and pancreatic cancer.
academia.edu